文献速递淋巴瘤

「别让我等待」:估算缩短静脉到静脉时间对美国三线及以上大B细胞淋巴瘤患者终身结局的影响

"Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes.
PubMed 文献 · Blood Adv · 2024-01-01

本研究用数学模型估算缩短静脉到静脉时间(V2VT)对接受CAR-T治疗的三线及以上复发/难治性大B细胞淋巴瘤(R/R LBCL)患者终身结局的影响。将V2VT从54天(tisa-cel中位V2VT;JULIET)缩短至24天(axi-cel中位V2VT;ZUMA-1),每例患者预期寿命增加3.2年(4.2 vs 7.7生命年),增加2.4个质量调整生命年(3.2 vs 5.6),且在美国常规支付意愿阈值下具有成本效果。

要点

  • V2VT从54天缩短至24天,每例患者生命年4.2 vs 7.7,增加3.2年。
  • 同一比较中质量调整生命年3.2 vs 5.6,增加2.4个。
  • 较短V2VT在美国常规支付意愿阈值下具有成本效果。

核心结论

  • 缩短V2VT可改善三线及以上R/R LBCL接受CAR-T治疗患者的终身结局,凸显通过更快生产时间和优化医院交付实现及时输注的重要性。

研究设计与样本

  • 研究建立数学模型,估算假设队列中长期与短期V2VT患者的终身结局,并估算生命年、质量调整生命年和成本。
  • 对关键假设进行情景分析以评估结果的稳健性。

主要发现

  • V2VT从54天(tisa-cel中位V2VT;JULIET)缩短至24天(axi-cel中位V2VT;ZUMA-1),每例患者生命 expectancy增加3.2年(4.2 vs 7.7生命年)。
  • 同一比较中每例患者增加2.4个质量调整生命年(3.2 vs 5.6)。
  • 较短V2VT在美国常规支付意愿阈值下具有成本效果。
  • 结果由更高的输注率和输注者中CAR-T更好的疗效驱动。
  • 使用较小V2VT差异(24 vs 36天)的情景分析产生一致结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor T-cell therapy (CAR T) has revolutionized the treatment of hematological cancers. Its production requires a complex logistical process, and the time from leukapheresis to patient infusion (known as the vein-to-vein time [V2VT]) can be long during which a patients clinical condition may deteriorate. This study was designed to estimate the benefits of reduced V2VT for third-line or later (3L+) relapsed/refractory large B-cell lymphoma (R/R LBCL) patients treated with CAR T. A mathematical model was developed to estimate the lifetime outcomes of a hypothetical cohort of patients who had either a long or short V2VT. Life-years (LYs), quality-adjusted LYs (QALYs), and costs were estimated. Scenario analyses were performed to assess the robustness of results to key assumptions. The results of the model show that reducing V2VT from 54 days (tisa-cel median V2VT; JULIET) to 24 days (axi-cel median V2VT; ZUMA-1) led to a 3.2-year gain in life expectancy (4.2 vs 7.7 LYs), and 2.4 additional QALYs (3.2 vs 5.6) per patient. Furthermore, a shorter V2VT was shown to be cost-effective under conventional willingness-to-pay thresholds in the United States. Results are driven by a higher infusion rate and a better efficacy of CAR T for those infused. Scenario analyses using a smaller difference in V2VT (24 vs 36 days) produced consistent results. Our study is the first to quantify lifetime V2VT-related outcomes for 3L+ R/R LBCL patients treated with CAR T utilizing currently available evidence. Shorter V2VTs led to improved outcomes, demonstrating the importance of timely infusion achievable by faster manufacturing times and optimization of hospital delivery.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vadgama S, Pasquini MC, Maziarz RT, et al. "Don't keep me waiting": estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood Adv. 2024. PMID: 38662645. doi:10.1182/bloodadvances.2023012240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。